RxDoctor Payments Data

Franklin Fleischhauer, MD

Cardiovascular Disease · Pensacola, FLNPI 1275533788

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $138,527 of the $154,690 with a category attached, or 89.6%. 34 manufacturers reported payments, led by Boehringer Ingelheim at 29.6% of the total. Reporting peaked in 2024 at $49,431 and has fallen 80.2% since, to $9,772 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$154,690in general payments, 2019–2025

Across 468 payments — averaging $330.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$46K
  • Lilly USA, LLC$39K
  • Boston Scientific$34K
  • Sanofi-aventis U.S. LLC$25K
  • Regeneron Healthcare Solutions, Inc.$5K
  • Amgen$720
  • plus $5K from 28 others
$73,818in research payments, 2019–2025

Across 10 payments — averaging $7381.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$61K
  • Amgen$11K
  • Abbott$2K

What the payments were for

  • Speaking & faculty fees$138,52790%
  • Travel & lodging$4,7483%
  • Food & beverage$11,4157%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$154,690 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida →

Medicare billing

Part B allowed, 2024
$138,653
Medicare patients
749
Services billed
1,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban280$350,587
Repatha SureclickEvolocumab185$196,719
EntrestoSacubitril/Valsartan114$170,987
JardianceEmpagliflozin55$55,554
XareltoRivaroxaban30$47,367
NexletolBempedoic Acid29$24,490
Praluent PenAlirocumab18$24,138
VascepaIcosapent Ethyl22$18,881
LivaloPitavastatin Calcium18$10,883
Metoprolol Succinate575$10,485
Ezetimibe340$9,380
Icosapent Ethyl17$8,296
Rosuvastatin Calcium451$7,743
Ranolazine ErRanolazine50$6,998
Losartan Potassium531$6,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$437$350,587280 claims
NovartisEntresto$403$170,987114 claims
Boehringer IngelheimJardiance$45,743$55,55455 claims
Johnson & JohnsonXarelto$309$47,36730 claims
Esperion Therapeutics, Inc.Nexletol$273$24,49029 claims
Kowa Pharmaceuticals America, Inc.Livalo$89$10,88318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Pensacola

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →